The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
…
continue reading
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
…
continue reading
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us ...
…
continue reading
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest ...
…
continue reading
Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Eva ...
…
continue reading
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, ...
…
continue reading
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
1
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024
24:59
24:59
Play later
Play later
Lists
Like
Liked
24:59
This week's podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel,…
…
continue reading
The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab to treat non-small cell lung cancer that has captured the industry writ large encouraged us to revisit the topic. To date, there hav…
…
continue reading
1
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part Series
58:36
58:36
Play later
Play later
Lists
Like
Liked
58:36
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.By Neil Love, MD
…
continue reading
1
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
56:11
56:11
Play later
Play later
Lists
Like
Liked
56:11
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.By Neil Love, MD
…
continue reading
1
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more!
21:36
21:36
Play later
Play later
Lists
Like
Liked
21:36
Today's podcast episode focuses on the management of complications associated with Waldenström's macroglobulinemia (WM), featuring expert insights from the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) held in Prague, Czech Republic. You will hear from Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, UK…
…
continue reading
1
Episode: 23 - An Industry Veteran’s Insight on Data Governance and Provenance
16:49
16:49
Play later
Play later
Lists
Like
Liked
16:49
In this episode of Evaluating Biopharma, host Ben Locwin and Scott Endicott, executive leader of Healthcare Solutions Integration, talk about data governance and data provenance—why they matter and how the industry can achieve them. With 30 years of experience, Endicott has a deep understanding of training AI and ML models, particularly when patien…
…
continue reading
1
Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field
42:34
42:34
Play later
Play later
Lists
Like
Liked
42:34
November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload tech…
…
continue reading
1
What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma
56:14
56:14
Play later
Play later
Lists
Like
Liked
56:14
Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.By Neil Love, MD
…
continue reading
1
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
22:39
22:39
Play later
Play later
Lists
Like
Liked
22:39
This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix, AZ. You will hear from Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Guillermo Montalban-Bravo, MD, The Universit…
…
continue reading
1
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events
9:29
9:29
Play later
Play later
Lists
Like
Liked
9:29
Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, H…
…
continue reading
1
Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma
57:58
57:58
Play later
Play later
Lists
Like
Liked
57:58
Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erika Hamilton, MD The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Douglas Tremblay, MD Based on three randomized-controlled trials, the JAK inhibitor momelotinib has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly in patients with myelofibrosis. But what do we know about its long-term safety? That’s what a recent study explor…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mary Frances McMullin, MD The MOMENTUM study evaluated the impact of the treatment option momelotinib on patient-reported outcomes, including symptom burden and overall quality of life. Joining Dr. Charles Turck to share the key findings and potential implications for myelofibrosis care is Dr. Mary Fr…
…
continue reading
1
Practical Perspectives: Current Management of Chronic Myeloid Leukemia
1:49:21
1:49:21
Play later
Play later
Lists
Like
Liked
1:49:21
Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.By Neil Love, MD
…
continue reading
1
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!
16:34
16:34
Play later
Play later
Lists
Like
Liked
16:34
Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help…
…
continue reading
1
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
20:40
20:40
Play later
Play later
Lists
Like
Liked
20:40
In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including: 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D The role of bispecific antibodies in R/R MM Safety considerations for patients while receiving a bispecific antibody Emerging…
…
continue reading
1
Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma
46:32
46:32
Play later
Play later
Lists
Like
Liked
46:32
Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.By Neil Love, MD
…
continue reading
1
Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond
39:43
39:43
Play later
Play later
Lists
Like
Liked
39:43
October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more success…
…
continue reading
1
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations
28:28
28:28
Play later
Play later
Lists
Like
Liked
28:28
In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including: The diagnosis and typical presenting symptoms of GEP-NETs Findings from recent key phase III studies including NETTER-2 and CABINET Recommendations for treatment sequencing No…
…
continue reading
Host: Gates B. Colbert, MD Guest: Ryan Cassaday, MD According to the available long-term data, CAR T-cell therapy boosts overall survival and durable remission rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Given this data, it’s important to know how we can best identify appropriate patients for this approac…
…
continue reading
1
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024
20:30
20:30
Play later
Play later
Lists
Like
Liked
20:30
Today's podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster,…
…
continue reading
1
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series
58:58
58:58
Play later
Play later
Lists
Like
Liked
58:58
Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.By Neil Love, MD
…
continue reading
1
Prolonging remission in AML: current approaches & future outlooks
31:27
31:27
Play later
Play later
Lists
Like
Liked
31:27
Today's podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focu…
…
continue reading
1
Episode: 22 - Insider’s Advice for Starting, Growing, Exiting a Biotech
35:01
35:01
Play later
Play later
Lists
Like
Liked
35:01
In this month’s episode of Evaluating Biopharma, host Ben Locwin and Chris Major, founder and partner of BioProcess360 Partners, discuss the best ways to start a company to address technology gaps, why it is beneficial to collaborate with competitors (instead of going against each other), and the challenges encountered when planning to de-risk port…
…
continue reading
Host: Matt Birnholz, MD The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive managem…
…
continue reading
1
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
30:45
30:45
Play later
Play later
Lists
Like
Liked
30:45
In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including: Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced…
…
continue reading
In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They focus on key drivers affecting markets this year and discuss the recent news of the Fed’s decision to cut interest rates by 50-basis…
…
continue reading
1
A focus on the use of artificial intelligence to personalize blood cancer care
28:55
28:55
Play later
Play later
Lists
Like
Liked
28:55
Welcome to the final episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used i…
…
continue reading
1
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
32:48
32:48
Play later
Play later
Lists
Like
Liked
32:48
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including: Contemporary treatment paradigms for patients with CLL Safety and efficacy of current regimens Molecular testing, including when and how to test for BTK inhibitor res…
…
continue reading
1
A focus on pediatric leukemias: trials, treatments, & challenges
17:44
17:44
Play later
Play later
Lists
Like
Liked
17:44
Welcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series! The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acu…
…
continue reading
1
A focus on the psychosocial impacts of living with blood cancer
36:22
36:22
Play later
Play later
Lists
Like
Liked
36:22
Welcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series! Today's episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights …
…
continue reading
1
From NASH to MASH: Current Market Dynamics in Hepatology
28:19
28:19
Play later
Play later
Lists
Like
Liked
28:19
After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH. The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic …
…
continue reading
Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. H…
…
continue reading
1
Episode: 21 - How AI is Changing the Antibody R&D Game
31:35
31:35
Play later
Play later
Lists
Like
Liked
31:35
In this month’s episode of Evaluating Biopharma, host Ben Locwin and Tony Arulanandam, SVP and head of R&D at Cytovia Therapeutics, discuss how AI is impacting the antibody R&D field, how companies are using AI to generate better sequences and improve efficacy, and methods on approaching regulators and tackling regulatory challenges. Arulanandam al…
…
continue reading
1
Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More
31:55
31:55
Play later
Play later
Lists
Like
Liked
31:55
September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, founder of FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his …
…
continue reading
1
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
18:54
18:54
Play later
Play later
Lists
Like
Liked
18:54
Welcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of b…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua E. Reuss, MD The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss…
…
continue reading